Results 21 to 30 of about 54,402 (291)
Mycobacteria attenuate nociceptive responses by formyl peptide receptor triggered opioid peptide release from neutrophils. [PDF]
PLoS Pathogens, 2009 In inflammation, pain is regulated by a balance of pro- and analgesic mediators. Analgesic mediators include opioid peptides which are secreted by neutrophils at the site of inflammation, leading to activation of opioid receptors on peripheral sensory ...
Heike L Rittner +9 more
doaj +1 more source
CXCL10 controls inflammatory pain via opioid peptide-containing macrophages in electroacupuncture. [PDF]
PLoS ONE, 2014 Acupuncture is widely used for pain treatment in patients with osteoarthritis or low back pain, but molecular mechanisms remain largely enigmatic. In the early phase of inflammation neutrophilic chemokines direct opioid-containing neutrophils in the ...
Ying Wang +5 more
doaj +1 more source
Molecules, 2023 Peptide-based opioid ligands are important candidates for the development of novel, safer, and more effective analgesics to treat pain. To develop peptide-based safer analgesics, we synthesized a mixture-based cyclic pentapeptide library containing a ...
Yangmei Li +5 more
doaj +1 more source
Biomolecules, 2020 The peptide AVFQHNCQE demonstrated to produce nitric oxide-mediated antihypertensive effect. This study investigates the bioavailability and the opioid-like activity of this peptide after its oral administration.
Anna Mas-Capdevila +5 more
doaj +1 more source
Molecules, 2020 The macrocyclic tetrapeptide cyclo[Phe-d-Pro-Phe-Trp] (CJ-15,208) and its stereoisomer cyclo[Phe-d-Pro-Phe-d-Trp] exhibit different opioid activity profiles in vivo.
Ariana C. Brice-Tutt +7 more
doaj +1 more source
LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief
Molecules, 2021 Although persistent pain is estimated to affect about 20% of the adult population, current treatments have poor results. Polypharmacology, which is the administration of more than one drug targeting on two or more different sites of action, represents a ...
Lorella Pasquinucci +5 more
doaj +1 more source
Current Medicinal Chemistry, 2016 For decades the opioid receptors have been an attractive therapeutic target for the treatment of pain. Since the first discovery of enkephalin, approximately a dozen endogenous opioid peptides have been known to produce opioid activity and analgesia, but their therapeutics have been limited mainly due to low blood brain barrier penetration and poor ...
Michael Remesic +2 more
openaire +3 more sources
Molecules, 2020 The mu opioid receptor (MOR) is the primary target for analgesia of endogenous opioid peptides, alkaloids, synthetic small molecules with diverse scaffolds, and peptidomimetics.
Maria Dumitrascuta +4 more
doaj +1 more source
Molecules, 2021 Activated opioid receptors transmit internal signals through two major pathways: the G-protein-mediated pathway, which exerts analgesia, and the β-arrestin-mediated pathway, which leads to unfavorable side effects. Hence, G-protein-biased opioid agonists
Yusuke Karasawa +12 more
doaj +1 more source
Protective Role and Functional Engineering of Neuropeptides in Depression and Anxiety: An Overview
Bioengineering, 2023 Behavioral disorders, such as anxiety and depression, are prevalent globally and touch children and adults on a regular basis. Therefore, it is critical to comprehend how these disorders are affected.
Nathalie Okdeh +7 more
doaj +1 more source